Denmark’s Novo Nordisk (NOV: N) saw its shares rise as much as 13% to 659.20 kroner this morning, after it announced top-line results from a Phase Ib/IIa clinical trial with amycretin once weekly subcutaneous (SC) administration.
Amycretin is both an amylin and GLP-1 receptor agonist and a once-daily oral option, unlike the firm’s blockbuster obesity drug Wegovy (semaglutide), which is an injectable medication, as is Eli Lilly’s (NYSE: LLY) chief rival the GLP-1 receptor agonist tirzepatide, trade named Mounjaro and Zepbound, as well as the other leading weight loss drugs on the market.
Analysts at Bank of America said the results showed amycretin could be “best in class,” delivering as much as 25% weight loss. But the drug still needs to go through a large late-stage trial, so would not be on the market until at least 2028, they said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze